The U.S.Unfractionated Heparin Market, by Source (Porcine and Bovine), by InjectionType (IV Injection and Subcutaneous Injection), and by Disease Indication(Venous Thromboembolism, Cardioversion of Atrial Fibrillation, and PulmonaryEmbolism & Arterial Embolism), was valued at US$ 335.4 million in 2018 andis expected to exhibit a CAGR of 4.5% over the forecast period (2019 – 2027),as highlighted in a new report published by Coherent Market Insights.
Increasing prevalence ofthromboembolic diseases, owing to the rising number of obese and olderpopulation in U.S. is expected to drive growth of the U.S. unfractionatedheparin market over the forecast period. For instance, according to theCirculation Research Journal, a journal of the American Heart Association(AHA), in 2016, in the U.S., study estimates showed that age-stratifiedincidence was 143 per 100,000 among people of age 40 to 49 years, 200 per100,000 among people of age 50 to 59 years, 391 per 100,000 among people of age60 to 69 years, 727 per 100,000 among people of age 70 to 79 years, and 1,134per 100,000 among people of age ≥80 years.
Major players are focusing onacquisitions to expand their product portfolio and presence in the market,which is expected to drive the market growth over the forecast period. Forinstance, in July 2016, Nichi-Iko Pharmaceutical Co., Ltd acquired SagentPharmaceuticals, Inc., a U.S.-based manufacturer of pharmaceutical injectable,valued at US$ 736 million. This acquisition enhanced Nichi-Iko’s presence inthe U.S. market to commercialize its biosimilar product portfolio.
* The sample copy includes: Report Summary, Table ofContents, Segmentation, Competitive Landscape, Report Structure, Methodology.
Request a sample copyof this report: https://www.coherentmarketinsights.com/insight/request-sample/3187
Browse 12 Market Data Tables and10 Figures spread through 82 Pages and in-depth TOC on ‘U.S. UnfractionatedHeparin Market’, by Source (Porcine and Bovine), by Injection Type (IVInjection and Subcutaneous Injection), and by Disease Indication (VenousThromboembolism, Cardioversion of Atrial Fibrillation, and Pulmonary Embolism& Arterial Embolism) - Global Forecast to 2027.
The U.S. unfractionated heparinmarket is expected to exhibit growth over the forecast period, owing toincreasing prevalence of thromboembolic diseases. For instance, according tothe Circulation Research Journal, a journal of the American Heart Association,in 2016, the study reported that the incidence of venous thromboembolism (VTE)is higher as age increases in the U.S.
Moreover, favorable regulatoryframework is also offering lucrative opportunity for growth of the market. Forinstance, in September 2019, the U.S. Food and Drug Administration (FDA)directed that all forms of imported heparin are subjected to compliance testing,in order to reduce risk of complication such as heparin inducedthrombocytopenia and deaths associated with imported heparin.
Browse ResearchReport: https://www.coherentmarketinsights.com/market-insight/us-unfractionated-heparin-market-3187
Key Takeaways of the U.S.Unfractionated Heparin Market:
The global U.S. unfractionatedheparin market is expected to exhibit a CAGR of 4.5% over the forecast period,owing to increasing cases of thromboembolism in the U.S. and acquisitionstrategies by players in the U.S. unfractionated heparin market
Among source, porcine segmentheld dominant position in the U.S. unfractionated heparin market in 2018, owingto the U.S. Food and Drug Administration (FDA) approval for sources used formanufacturing of heparin. For instance, the only commercially available sourcein U.S. for the heparin production is porcine, derived from porcine intestinalmucosa.
Among injection type, IVinjection segment held dominant position in the U.S. unfractionated heparinmarket in 2018, owing to rising mergers & acquisitions by market players.For instance, in September 2016, Baxter International Inc. acquired ClarisInjectable, an India-based generic injectable pharmaceutical company. Thisacquisition helped Baxter to increase the production of injectable such asanesthesia and analgesics, anti-infective, renal and critical care products.
Among disease indication, venousthromboembolism segment held dominant position in the U.S. unfractionatedheparin market in 2018, owing to rising cases of thromboembolism. According tothe data and statistics published by the National Center on Birth Defects and DevelopmentalDisabilities, a part of Centers for Disease Control and Prevention in March2019, venous thromboembolism (VTE) is the foremost cause of preventablehospital death in the U.S. Around 5.0% to 8.0% of the U.S. population has oneof the several genetic risk factors. It is also known as inheritedthrombophilias, wherein a genetic defect can be identified that increases therisk for thrombosis.
Companies operating in the globalU.S. unfractionated heparin market include Pfizer, Inc., Sagent Pharmaceuticals,Inc., B. Braun Melsungen AG, Baxter International Inc., and Bayer AG
Buy-Now this researchreport: https://www.coherentmarketinsights.com/insight/buy-now/3187
AboutCoherent Market Insights:
CoherentMarket Insights is a prominent market research and consulting firm offeringaction-ready syndicated research reports, custom market analysis, consultingservices, and competitive analysis through various recommendations related toemerging market trends, technologies, and potential absolute dollaropportunity.
ContactUs:
mailto:sales@coherentmarketinsights.com
U.S.Office:
Name: Mr. Shah
CoherentMarket Insights 1001 4th Ave,
# 3200Seattle, WA 98154, U.S.
US : +1-206-701-6702
UK : +44-020-8133-4027
JAPAN : +050-5539-1737
